Teijin Pharma will launch Ipsen's Somatuline subcutaneous injection in 60mg, 90mg and 120mg doses, indicated to treat acromegaly and pituitary gigantism, in Japan.
The medication is indicated for acromegaly and pituitary gigantism patients who cannot undergo surgical therapies or who do not considerably respond to surgical therapies.
Teijin Pharma president Kentaro Arao said, "Somatuline, used in more than 60 countries worldwide, is highly regarded by the medical profession and patients for its long-lasting effects and user-friendly dosing devices."
Synthetic somatostatin analog Somatuline is approved for single administered for every four weeks.
Somatuline is available in Japan along with a pre-filled syringe, which does not require reconstitution, and a retractable needle.
Ipsen operations executive vice-president Christophe Jean said, "We are privileged to have Teijin as our partner in Japan and pleased that Somatuline is now also available to Japanese patients suffering from acromegaly and pituitary gigantism."